Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H11O7.Na |
| Molecular Weight | 218.1371 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O
InChI
InChIKey=UPMFZISCCZSDND-JJKGCWMISA-M
InChI=1S/C6H12O7.Na/c7-1-2(8)3(9)4(10)5(11)6(12)13;/h2-5,7-11H,1H2,(H,12,13);/q;+1/p-1/t2-,3-,4+,5-;/m1./s1
| Molecular Formula | C6H11O7 |
| Molecular Weight | 195.1473 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P02792|||Q9BTZ8 Gene ID: 2512.0 Gene Symbol: FTL Target Organism: Homo sapiens (Human) Sources: https://www.drugbank.ca/drugs/DB09517 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Ferrlecit Approved UseFerrlecit is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. Launch Date1999 |
|||
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
12.9 μg/mL |
1.5 mg/kg single, intravenous dose: 1.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
GLUCONATE ION plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
95 μg × h/mL |
1.5 mg/kg single, intravenous dose: 1.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
GLUCONATE ION plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2 h |
1.5 mg/kg single, intravenous dose: 1.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
GLUCONATE ION plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive [IC50 35.5162 uM] | ||||
| inconclusive [IC50 63.1577 uM] | ||||
| no | ||||
| no | ||||
| yes [IC50 89.2126 uM] |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. | 2017-09 |
|
| The available intravenous iron formulations: History, efficacy, and toxicology. | 2017-06 |
|
| In vitro study on the effects of iron sucrose, ferric gluconate and iron dextran on redox-active iron and oxidative stress. | 2010 |
|
| Activation of P2X(7) receptors induced [(3)H]GABA release from the RBA-2 type-2 astrocyte cell line through a Cl(-)/HCO(3)(-)-dependent mechanism. | 2002-01 |
|
| Cloning of a Serratia marcescens DNA fragment that induces quinoprotein glucose dehydrogenase-mediated gluconic acid production in Escherichia coli in the presence of stationary phase Serratia marcescens. | 2001-12-18 |
|
| Ineffectiveness of intranasal zinc gluconate for prevention of experimental rhinovirus colds. | 2001-12-01 |
|
| Iron sucrose or ferric gluconate? | 2001-12 |
|
| Post-natal ontogeny of stanniocalcin gene expression in rodent kidney and regulation by dietary calcium and phosphate. | 2001-12 |
|
| An atypical chemical burn. | 2001-11-03 |
|
| Role of CFTR's PDZ1-binding domain, NBF1 and Cl(-) conductance in inhibition of epithelial Na(+) channels in Xenopus oocytes. | 2001-11-01 |
|
| Aluminium toxicity and iron homeostasis. | 2001-11 |
|
| Functional atrioventricular block in a preterm infant. | 2001-11 |
|
| Physiological characterisation of Penicillium chrysogenum strains expressing the expandase gene from Streptomyces clavuligerus during batch cultivations. Growth and adipoyl-7-aminodeacetoxycephalosporanic acid production. | 2001-10 |
|
| Hypocalcemia in the newborn. | 2001-10 |
|
| Chemical mechanism of beta-xylosidase from Trichoderma reesei QM 9414: pH-dependence of kinetic parameters. | 2001-10 |
|
| Considerations for optimal iron use for anemia due to chronic kidney disease. | 2001-10 |
|
| 99mTc-labeling experiments on CCK(4) by a direct method. | 2001-10 |
|
| Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. | 2001-10 |
|
| Lack of allergic reaction to Ferrlecit in a patient with a history of severe pruritic reaction with INFeD. | 2001-10 |
|
| Imaging and localization of pancreatic insulinomas. | 2001-09-22 |
|
| Anion modulation of the slowly activating vacuolar channel. | 2001-09-15 |
|
| Identification and determination of glucuronides and their aglycones in Erigeron breviscapus by liquid chromatography-tandem mass spectrometry. | 2001-09-14 |
|
| Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. | 2001-09-11 |
|
| Significance of interferon-gamma in coronary artery bypass surgery. | 2001-09-11 |
|
| Hydrofluoric acid burn from a household rust remover. | 2001-09-03 |
|
| Background osmolyte current involved in cell volume regulation of neuroblastoma x glioma hybrid NG108-15 cells. | 2001-09 |
|
| On-line coupling of a miniaturized bioreactor with capillary electrophoresis, via a membrane interface, for monitoring the production of organic acids by microorganisms. | 2001-09 |
|
| Thioglucosidase activity from Sphingobacterium sp. strain OTG1. | 2001-09 |
|
| [Possible treatments of glottic spasm]. | 2001-09 |
|
| Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin-secreting tumours. | 2001-09 |
|
| Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025-6. | 2001-09 |
|
| Solubility and relative absorption of copper, iron, and zinc in two milk-based liquid infant formulae. | 2001-09 |
|
| CFTR modulates programmed cell death by decreasing intracellular pH in Chinese hamster lung fibroblasts. | 2001-09 |
|
| Water-soluble adamantane-terminated dendrimers possessing a rhenium core. | 2001-08-10 |
|
| Properties and modulation of alpha human atrial natriuretic peptide (alpha-hANP)-formed ion channels. | 2001-08 |
|
| Electricity and the treatment of hydrofluoric acid burns--the wave of the future or a jolt from the past? | 2001-08 |
|
| Iontophoretic delivery of calcium for experimental hydrofluoric acid burns. | 2001-08 |
|
| Fatal unintentional occupational poisonings by hydrofluoric acid in the U.S. | 2001-08 |
|
| Clinical features, tissue smear and competitive enzyme linked immunosorbent assay as dignostic and prognostic procedures for visceral leishmaniasis in Yemen. | 2001-08 |
|
| Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. | 2001-07 |
|
| Cadmium in zinc-containing mineral supplements. | 2001-07 |
|
| Substrate selectivity of Gluconobacter oxydans for production of 2,5-diketo-D-gluconic acid and synthesis of 2-keto-L-gulonic acid in a multienzyme system. | 2001-06 |
|
| Single K+ channels in endocrine cells dispersed from the cricket (Gryllus bimaculatus) corpora allata. | 2001-06 |
|
| Effects of P5, a novel oxazolo(3,2-a)pyridine derivative with a long-acting antihypertensive activity, on different agonist-mediated pressor responses in pithed rats. | 2001-04 |
|
| Calcium L-edge XANES study of some calcium compounds. | 2001-03-01 |
|
| Novel degradable polymers combining D-gluconic acid, a sugar of vegetal origin, with lactic and glycolic acids. | 2001 |
|
| Development of a process for the biotechnological large-scale production of 4-hydroxyvalerate-containing polyesters and characterization of their physical and mechanical properties. | 2001 |
|
| Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures. | 2001 |
|
| Biosynthesis of poly(3-hydroxybutyrate-co-3-mercaptobutyrate) as a sulfur analogue to poly(3-hydroxybutyrate) (PHB). | 2001 |
|
| Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. | 2001 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28391437
8 weeks of IV ferric gluconate 125 mg weekly
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4026827
The effect of iron(III)-gluconate (Ferlixit) at various concentrations
on the malondialdehyde production in isolated rat liver mitochondria
was studied. Concentratiors of iron as low as 100 uM are
able to elicit a significant enhancement of lipid peroxidation.
process.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:36:48 GMT 2025
by
admin
on
Mon Mar 31 17:36:48 GMT 2025
|
| Record UNII |
R6Q3791S76
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-576
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
||
|
DSLD |
3141 (Number of products:1)
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
||
|
JECFA EVALUATION |
INS-576
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
||
|
NCI_THESAURUS |
C360
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
208-407-7
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
R6Q3791S76
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
4214
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
SUB21570
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
759599
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
100000091524
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
DTXSID7027170
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
23672301
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
m5762
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL2068884
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
56476
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | RxNorm | ||
|
C47723
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
DBSALT002440
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
C030691
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
527-07-1
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
R6Q3791S76
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
84997
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY | |||
|
SODIUM GLUCONATE
Created by
admin on Mon Mar 31 17:36:48 GMT 2025 , Edited by admin on Mon Mar 31 17:36:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
||
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|